Abstract Search

ea0047oc8 | Spotlight on Neuroendocrine tumours | Theranostics2016

NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis

Strosberg Jonathan , Wolin E , Chasen B , Kulke M , Bushnell D , Caplin M , Baum R P , Kunz P , Hobday T , Hendifar A , Oberg K , Lopera Sierra M , Kwekkeboom D , Ruszniewski P , Krenning E

Background: Currently, there are limited therapeutic options for patients with advanced midgut neuroendocrine tumors progressing on first-line somatostatin analog therapy.Methods: NETTER-1 is the first phase III, randomized trial evaluating 177Lu-DOTA0-Tyr3-Octreotate (Lutathera®) in patients with progressive, somatostatin receptor positive midgut NETs. 230 patients were randomized to receive Lutathera 7.4...

0 shares

ea0046oc3 | (1) | UKINETS2016

Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period

Horsch D , Kulke M , Caplin M , Anthony L , Bergsland E , Oberg K , Welin S , Warner R , Lombard-Bohas C , Kunz P , Valle J , Fleming D , Lapuerta P , Banks P , Pavel M

Introduction: TELESTAR was a pivotal, randomized phase 3 study evaluating telotristat etiprate (TE), a tryptophan hydroxylase inhibitor, among patients (pts) with carcinoid syndrome (CS). When added to somatostatin analogues (SSA), 250 mg tid and 500 mg tid TE each produced significantly greater bowel movement (BM) frequency reduction averaged over 12 weeks (wks) than placebo (PBO) plus SSA (P<0.001). Pts crossed over to open-label (OL) treatment with TE 500 mg ti...

0 shares

Endocrine Abstracts

NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis

Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period

BiosciAbstracts